Financial Data and Key Metrics Changes - Total revenues for Q3 2025 were $0.4 million, reflecting royalties from Ayrmid for APHEXDA commercialization, a significant decrease compared to the previous year due to the upfront payment received under the Gloria license agreement in 2024 [17][18] - Research and development expenses decreased to $1.7 million from $2.6 million in Q3 2024, primarily due to lower expenses related to metixafortide and a reduction in headcount [18][19] - Net loss for Q3 2025 was $1 million, a substantial decrease from a net loss of $5.8 million in Q3 2024 [19] Business Line Data and Key Metrics Changes - APHEXDA generated sales of $2.4 million in Q3 2025, resulting in $0.4 million of royalty revenue to the company [13][14] - The company continues to support the development of metixafortide in pancreatic cancer, with ongoing trials that could represent significant value inflection points [12][16] Market Data and Key Metrics Changes - The total addressable market for glioblastoma in the U.S. and Europe is estimated to exceed $3.7 billion, with an expected annual incidence of approximately 18,500 patients in the U.S. by 2030 [8][9] - The unmet need in glioblastoma treatment is significant, with current standard care established over 20 years ago and limited improvements since [7][8] Company Strategy and Development Direction - The company has established a joint venture with Hemispherian to develop GLIX1, a novel molecule targeting glioblastoma and other cancers, leveraging both companies' strengths [3][4] - The strategy includes expanding GLIX1's development into additional cancer indications once safety and dosing are established [10][11] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential of GLIX1 and its unique mechanism of action, which could provide significant advancements in cancer treatment [9][10] - The company remains focused on creating long-term value for shareholders while addressing significant unmet medical needs in oncology [13][19] Other Important Information - The company ended Q3 2025 with cash and equivalents of approximately $25.2 million, sufficient to fund operations into the first half of 2027 [13][19] - A key patent for GLIX1 has been allowed, broadening its protection until at least 2040, with potential extensions [10][11] Q&A Session Summary Question: Insights on upcoming clinical study for GLIX1 and potential PD markers - Management confirmed plans to collect extensive pharmacokinetic data and mentioned challenges in obtaining pharmacodynamic markers due to the nature of the trial [22][23] Question: Intermediate manufacturing capacity needs for GLIX1 - The company stated that current manufacturing capacity is sufficient for Phase II-A trials, with no anticipated changes needed [25] Question: Timeline for preclinical data readouts for additional tumor indications - Management indicated that results from preclinical models are being performed, with plans to present findings at conferences next year [26] Question: Medium-term market penetration targets for APHEXDA - Management clarified that they cannot provide guidance on market penetration as they no longer own the asset in the territories held by Ayrmid [31] Question: Reasonable targets for overall survival improvement in GBM - Management noted that for newly diagnosed GBM, a median overall survival improvement of approximately two and a half months would be a benchmark for interest from established pharma [33] Question: Financial statement treatment of investments in the JV - Management confirmed that expenses related to the JV will be consolidated in their financial statements and reflected as R&D expenses [35][36]

Financial Data and Key Metrics Changes - Total revenues for Q3 2025 were $0.4 million, reflecting royalties from ARAMID for Effexta commercialization, a significant decrease compared to the previous year due to the absence of upfront payments and direct sales [17][18] - Research and development expenses decreased to $1.7 million from $2.6 million in Q3 2024, primarily due to lower expenses related to metixafortide and a reduction in headcount [18][19] - Net loss for Q3 2025 was $1 million, a substantial improvement from a net loss of $5.8 million in Q3 2024 [19] Business Line Data and Key Metrics Changes - Effexta generated sales of $2.4 million in Q3 2025, resulting in $0.4 million of royalty revenue to the company [13][14] - The company continues to support the development of metixafortide in pancreatic cancer, with a phase 2b clinical trial ongoing [12] Market Data and Key Metrics Changes - The total addressable market for glioblastoma in the U.S. and Europe is estimated to exceed $3.7 billion, with an expected annual incidence of approximately 18,500 patients in the U.S. by 2030 [8] Company Strategy and Development Direction - The company established a joint venture with Hemispherian to develop GLIX1, a novel treatment for glioblastoma, leveraging both companies' strengths in clinical and regulatory success [3][4] - The company plans to initiate a phase 1/2a trial for GLIX1 in the first quarter of next year, with data anticipated in the first half of 2027 [5][8] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential of GLIX1 to address significant unmet needs in glioblastoma treatment, highlighting the poor prognosis and limited advancements in current therapies [7][8] - The company remains focused on creating long-term value for shareholders while advancing innovative cancer treatments [13] Other Important Information - The company ended Q3 2025 with cash and equivalents of approximately $25.2 million, sufficient to fund operations into the first half of 2027 [19] - A new patent for GLIX1 broadens its protection until 2040, with potential extensions, enhancing its competitive position in the market [10][11] Q&A Session Summary Question: What potential pharmacodynamic markers will be released during the GLIX1 clinical study? - Management plans to collect extensive pharmacokinetic data and will utilize biopsies if surgeries occur during the trial to gather pharmacodynamic markers [22][23] Question: What are the intermediate manufacturing needs for GLIX1? - The current manufacturer has sufficient capacity for the needs of the phase II-A trial, with no anticipated changes [25] Question: When might preclinical data for additional tumor indications be available? - Results from preclinical models are being performed, with plans to present findings at conferences next year [26] Question: What is the medium-term target for market penetration of Effexta? - Management indicated they cannot provide guidance on market penetration as they no longer own the asset in the territories held by ARAMID [31] Question: What improvement in overall survival for GBM would attract interest from established pharma? - For newly diagnosed GBM, an improvement of approximately two and a half months in median overall survival would be significant [33] Question: How will investments in the joint venture appear on financial statements? - The joint venture will be consolidated in the financial statements, with all expenses reflected as research and development expenses [35][36]

Financial Data and Key Metrics Changes - Total revenues for Q3 2025 were $0.4 million, reflecting royalties from ARAMID for Effexta commercialization, a significant decrease compared to the previous year due to the absence of upfront payments from Gloria Biosciences [17][18] - Research and development expenses decreased to $1.7 million from $2.6 million in Q3 2024, primarily due to lower expenses related to metixafortide and a reduction in headcount [18] - Net loss for Q3 2025 was $1 million, a substantial improvement from a net loss of $5.8 million in Q3 2024 [19] Business Line Data and Key Metrics Changes - Effexta generated sales of $2.4 million in Q3 2025, resulting in $0.4 million of royalty revenue to BioLineRx [13][14] - The company continues to support the development of metixafortide in pancreatic cancer, with a phase 2b clinical trial ongoing [12] Market Data and Key Metrics Changes - The total addressable market for glioblastoma is estimated to exceed $3.7 billion in the U.S. and Europe, with an expected annual incidence of approximately 18,500 patients in the U.S. by 2030 [8][9] Company Strategy and Development Direction - The establishment of a joint venture with Hemispherian aims to develop GlyxOne, a novel treatment for glioblastoma and other cancers, leveraging both companies' strengths [4][5] - The company plans to initiate a phase 1/2a glioblastoma trial in Q1 2026, with data anticipated in the first half of 2027 [8][9] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about GlyxOne's potential to address significant unmet needs in glioblastoma treatment, highlighting the poor prognosis and limited advancements in current therapies [6][7] - The company remains focused on creating long-term value for shareholders while advancing innovative cancer treatments [13] Other Important Information - The company ended Q3 2025 with cash and equivalents of approximately $25.2 million, sufficient to fund operations into the first half of 2027 [19] - GlyxOne has received a notice of allowance for a key patent, broadening its protection until at least 2040 [10][11] Q&A Session Summary Question: Insights on upcoming clinical study for GlyxOne - Management confirmed plans to collect extensive pharmacokinetic data and mentioned challenges in obtaining pharmacodynamic markers due to the nature of the study [22][23] Question: Medium-term market penetration targets for Effexta - Management stated they cannot provide guidance on market penetration as they no longer own the asset in the territories held by ARAMID [30] Question: Reasonable targets for overall survival improvement in GBM - Management indicated that for newly diagnosed GBM, a median overall survival improvement of approximately two and a half months would be a sufficient benchmark [31][32] Question: Financial statement treatment of JV investments - Management clarified that expenses related to the JV will be consolidated in their financial statements and reflected as R&D expenses [33][34]

Core Insights - BioLineRx Ltd. has established a joint venture with Hemispherian AS to develop GLIX1, an oral small molecule targeting DNA damage response in glioblastoma and other cancers, with a Phase 1/2a clinical trial expected to start in Q1 2026 [1][15] - The company reported unaudited financial results for Q3 2025, highlighting a net loss of $1.0 million, a significant reduction from a net loss of $5.8 million in Q3 2024 [11][16] Corporate Updates - The joint venture with Hemispherian aims to expand BioLineRx's development pipeline into high-need cancer indications, particularly glioblastoma, which has a projected global market of over $3.7 billion by 2030 [6][15] - The ongoing CheMo4METPANC Phase 2b clinical trial of motixafortide in metastatic pancreatic cancer continues to progress, providing another opportunity for innovation in cancer treatment [2][12] Financial Updates - As of September 30, 2025, BioLineRx had $25.2 million in cash, sufficient to fund operations into the first half of 2027 [4][16] - Total revenues for Q3 2025 were $0.4 million, primarily from royalties related to the commercialization of APHEXDA, compared to $4.9 million in Q3 2024 [11][20] - Research and development expenses decreased by 33% to $1.7 million in Q3 2025, attributed to lower costs associated with motixafortide following the out-licensing of U.S. rights [16][20] Clinical Updates - Preparations for the Phase 1/2a clinical trial of GLIX1 in glioblastoma are advancing, with leading investigators from Northwestern University set to oversee the study [7][12] - The trial will assess GLIX1 as a monotherapy and in combination with standard care and PARP inhibitors in various cancer types [12][15] - A poster presentation at the upcoming ASH Annual Meeting will feature results from a Phase 1 trial evaluating motixafortide for mobilizing CD34+ hematopoietic stem cells in sickle cell disease [12][16]

Core Points - BioLineRx Ltd. will release its unaudited financial results for Q3 2025 on November 24, 2025, before U.S. markets open [1] - A conference call will be held at 8:30 a.m. EST featuring remarks by CEO Philip Serlin [2] Company Overview - BioLineRx Ltd. is a biopharmaceutical company focused on developing therapies in oncology and rare diseases [4] - The company's first approved product is APHEXDA® (motixafortide), indicated for stem cell mobilization in multiple myeloma, commercialized by Ayrmid Ltd. globally (except Asia) and Gloria Biosciences in Asia [4] - BioLineRx retains rights to develop motixafortide for metastatic pancreatic cancer (PDAC) and is conducting a Phase 2b trial in collaboration with Columbia University [4] - The company has a joint venture with Hemispherian AS to develop GLIX1, an oral small molecule targeting DNA damage response in glioblastoma and other solid tumors, with a Phase 1/2a clinical trial planned for Q1 2026 [5]

Core Insights - BioLineRx Ltd. has received a Notice of Allowance from the U.S. Patent and Trademark Office for a key patent covering the use of GLIX1 in treating cancers where cytidine deaminase (CDA) is not over-expressed, which accounts for over 90% of all cancers [1][2][3] - The patent extends GLIX1's protection until at least 2040, with a potential five-year extension, allowing the company to explore its application in various cancer types beyond glioblastoma [1][4] Company Overview - BioLineRx is a clinical development stage biopharmaceutical company focused on therapies in oncology and rare diseases, with its first approved product being APHEXDA® for stem cell mobilization in multiple myeloma [4][9] - The company is preparing to initiate a first-in-human study of GLIX1 in glioblastoma patients in Q1 2026 while advancing pre-clinical studies in other cancer models [3][5] Intellectual Property - The newly allowed patent is a significant addition to GLIX1's intellectual property portfolio, which includes both issued and pending patents that cover its use as a monotherapy and in combination with established anti-cancer agents [3][5] - GLIX1 is also covered by pending international patent applications for its use in treating homologous recombination proficient cancers, potentially extending patent protection until at least 2044 [5]

Core Viewpoint - BioLineRx and Hemispherian have established a joint venture, which was announced in a press release and is available in the Investor Relations section of BioLineRx's website [2]. Group 1 - The announcement was made during a conference call led by Irina Koffler, Head of Investor Relations and Corporate Communications at BioLineRx [2]. - The company has filed the announcement as a 6-K with the U.S. Securities and Exchange Commission [2][3]. - Forward-looking statements were made during the call, indicating that actual results may differ from these projections due to various risks and uncertainties [2][3].

Core Points - BioLineRx and Hemispherian have established a joint venture [2] - The announcement was made during a conference call and a press release was issued [2] - The press release is available in the Investor Relations section of BioLineRx's website and was filed as a 6-K [2] Company Overview - Irina Koffler serves as the Head of Investor Relations and Corporate Communications at BioLineRx [2] - Philip Serlin is the Chief Executive Officer of BioLineRx [3]

Summary of BioLineRx Update Conference Call Company and Industry Overview - **Company**: BioLineRx - **Industry**: Biotechnology, specifically focused on cancer therapeutics Key Points and Arguments 1. **Joint Venture Announcement**: BioLineRx has established a joint venture with Hemispherian AS to develop GLYCS1, a novel molecule targeting glioblastoma and other cancers [4][6][19] 2. **Focus on GLYCS1**: GLYCS1 is an oral small molecule that targets DNA damage response, showing promise in treating glioblastoma, an aggressive brain tumor with limited treatment options [6][8][10] 3. **Clinical Development Plans**: A phase 1-2A clinical trial for GLYCS1 is planned to start in Q1 2026, with the phase 1 part focusing on safety and tolerability in recurrent GBM patients [9][17][20] 4. **Market Opportunity**: The annual incidence of glioblastoma is projected to be around 18,500 patients in the U.S. and 13,400 in the EU5 by 2030, representing a combined addressable market of approximately $3.8 billion [10][11] 5. **Mechanism of Action**: GLYCS1 restores TET2 activity, leading to DNA breaks in cancer cells while sparing healthy cells, which is expected to enhance its efficacy [14][15] 6. **Preclinical Success**: GLYCS1 has demonstrated potent anti-tumor activity in preclinical models, including complete prevention of tumor growth in glioblastoma models [16][17] 7. **Intellectual Property**: GLYCS1 is protected by patents valid until at least 2040, with potential extensions, covering its use in various cancers [11][12][13] 8. **Financial Position**: BioLineRx has a cash runway extending into the first half of 2027, supported by royalties and milestone payments from existing partnerships [20][23] 9. **JV Structure**: Hemispherian holds 60% of the joint venture, with BioLineRx holding 40%, which can increase to 70% based on further investments [19] 10. **Future Pipeline**: The joint venture will also have the first look at other molecules in Hemispherian's pipeline, focusing on DNA repair [11][19] Additional Important Information - **Current Standard of Care**: The existing treatment for glioblastoma includes surgery, radiotherapy, and temozolomide, which only benefits 25% to 50% of patients [10] - **Patient Advocacy**: Hemispherian is building relationships with patient advocacy groups to facilitate clinical trial enrollment [21] - **Safety Profile**: GLYCS1 has shown excellent safety results in preclinical studies, indicating a favorable profile for human trials [31] - **Potential Combinations**: There is significant potential for GLYCS1 to be used in combination with PARP inhibitors, which may enhance treatment efficacy in various cancers [18][33] This summary encapsulates the critical insights from the BioLineRx update conference call, highlighting the company's strategic direction, clinical development plans, and market potential for GLYCS1.

GLIX1 Development - A joint venture with Hemispherian AS was established in September 2025 to develop GLIX1 for glioblastoma and other indications, with initial economic stakes of Hemispherian at 60% and BioLineRx at 40%, potentially increasing to 70% for BioLineRx [7, 8] - GLIX1 is set to begin Phase 1 development in H1 2026 and has received FDA IND clearance [8, 58] - GLIX1 enhances TET2 activity, leading to increased 5hmC levels and double-stranded DNA breaks in cancer cells, ultimately causing cell death [19, 24] - Preclinical data indicates GLIX1 shows efficacy in various cancer cell lines and addresses key challenges for GBM drug development, including good blood-brain barrier penetration [30, 44, 49] - A Phase 1/2a clinical trial for GLIX1 in recurrent and progressive GBM is expected to initiate in Q1 2026, with potential expansion cohorts for newly diagnosed GBM and combination therapy with PARPi [55, 57] Motixafortide and APHEXDA - APHEXDA (motixafortide) has been successfully developed and out-licensed for stem cell mobilization in multiple myeloma [4] - License agreements for APHEXDA include up to $87 million in commercial milestones and royalties on sales from 18%-23% in Asia, and up to $200 million in commercial milestones with tiered double-digit royalties on sales outside of Asia (excluding solid tumors) [5, 6] - In first-line PDAC, the Chemo4MetPanc pilot phase 2 clinical trial showed a 64% Overall Response Rate and a median PFS of 96 months [84, 89] - The Chemo4MetPanc randomized phase 2b clinical trial is ongoing, equally funded by Regeneron and BioLineRx, with full enrollment planned in 2027 [90, 94] Financial Status - The company reported cash of approximately $282 million as of June 30, 2025, with a cash runway into the first half of 2027 [96]